The Uromigos

The Uromigos
  • 5,0 (2)
  • MEDICINA
  • SEMANAL

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

  1. HACE 22 H

    Episode 479: Does the Timing of IO Infusion Impact Clinical Outcomes? A Critical Analysis

    This episode critically examines a recent Nature Medicine paper on the timing of immune therapy infusion in lung cancer, exploring the scientific plausibility, methodological concerns, and implications for future research. Tom, Brian and David McDermott debate the validity of the findings, the review process, and the need for rigorous prospective trials.

    40 min

  2. 16 FEB

    Episode 478: Prostate Cancer Working Group 4 (PCWG 4) criteria

    Summary This Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group criteria, highlighting the iterative process of developing guidelines that reflect the latest scientific evidence and clinical practices. The speakers discuss the new PCWG4 including new nomenclature, the role of imaging technologies like PSMA PET, and the importance of biomarkers and patient-reported outcomes in enhancing patient care and treatment efficacy. They emphasize the collaborative nature of the working groups and the ongoing need for adaptation in response to emerging data and technologies.

    46 min

  3. 11 FEB

    Episode 477: Uromigos Japan - GU Oncology 2025を総括!

    3人で前立腺癌、腎癌、尿路上皮癌の2025をレビューしました。

    39 min

  4. 9 FEB

    Episode 476: ASCO GU 2026 Preview

    In this podcast , the Uromigos discuss the upcoming ASCO GU conference. They delve into the latest research findings, including phase 3 trials, combination therapies, and the significance of biomarkers in treatment. The conversation highlights the importance of belzutifan in kidney cancer and explores the evolving landscape of prostate and bladder cancer treatments. The hosts also share their predictions and insights on how these developments may impact clinical practice.

    49 min

  5. 2 FEB

    Episode 475: Depth of Response and Overall Survival for IO-based Regimens in mRCC: Results of an FDA Analysis

    In this Uromigos podcast episode, Brian and Tom engage with Elaine Chang from the FDA to discuss an analysis of depth of response as an indicator of survival in kidney cancer trials. They explore the FDA's data analysis process, the significance of tumor shrinkage, and the implications of their findings on treatment outcomes. The conversation delves into the limitations of current measurement methods and the potential for using depth of response as an early signal in drug development.

    30 min

  6. 26 ENE

    Episode 474: Uromigos Shorts - IO-refractory Urothelial Cancer

    In this episode of the Uromigos podcast, Brian Rini, Tom Powles, and Karine Tawagi discuss the complexities of immunotherapy re-challenge in bladder cancer. They explore the current landscape, including the challenges of existing data, the importance of understanding patient responses, and the potential for future research in antibody-drug conjugates (ADCs). The conversation highlights the need for more definitive studies to guide treatment decisions and improve patient outcomes.

    31 min

  7. 19 ENE

    Episode 473: Uromigos Shorts - EMBARK and BCR Prostate Cancer

    In this podcast, the Brian, Tm and David Einstein discuss the EMBARK study and its implications for patients with biochemically relapsed prostate cancer. They explore the criteria for high-risk patients, the role of PSMA PET imaging, and the findings related to metastasis-free survival and overall survival. The conversation also delves into treatment strategies, adverse events, and patient perspectives on treatment decisions, ultimately highlighting the need for future research in this evolving field.

    34 min

  8. 12 ENE

    Episode 472: Uromigos Shorts - Variant Histology Bladder Cancer

    This podcast discusses the significance of variant histology in urothelial cancer, emphasizing the need for tailored treatment approaches based on histological features. Experts David Aggen, Tom Powles and Brian Rini explore various variant histologies, their implications for treatment, and the challenges in managing mixed histology tumors. The conversation highlights the importance of expert pathology reviews and the evolving landscape of neoadjuvant therapy in this field.

    27 min
Ver todo (476)

Valoraciones y reseñas

5
de 5
2 valoraciones

Información

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Ficha técnica

  • Creado por
    The Uromigos
  • Años en activo
    2020 - 2026
  • Episodios
    476
  • Clasificación
    Apto
  • Derechos de autor
    © The Uromigos
  • Sitio web del podcast
    The Uromigos

Quizá también te guste